The Myotonic Dystrophy Clinical Research Network (DMCRN) is a consortium of academic investigators devoted to clinical research and therapeutic trials in the myotonic dystrophies (DM1 and DM2).  The goal of the network is to advance clinical trial readiness for those living with myotonic dystrophy and the investigators working with them to advance treatments for the condition. 

The network is governed by a consortium agreement signed by 13 institutions from the United States, United Kingdom, Canada, European Union and New Zealand. Virginia Commonwealth University serves as the central coordinating site for the consortium, under the direction of Dr. Nicholas Johnson. Support from the network comes from a precompetitive coalition of industry partners, as well as the FDA, MDA, and MDF. 

Jennifer Raymond and Ruby Langeslay serve at Consortium Coordinators and work at Virginia Commonwealth University. They oversee study conduct at all sites and provide support and guidance to the site study teams